Levine M M, Hone D, Tacket C, Ferreccio C, Cryz S
Department of Medicine, University of Maryland School of Medicine, Baltimore 21201.
Res Microbiol. 1990 Sep-Oct;141(7-8):807-16. doi: 10.1016/0923-2508(90)90114-6.
In recent years there has been a resurgence of research to develop new and improved attenuated strains of Salmonella typhi to function as live oral vaccines against typhoid fever and to serve as "carrier" vaccines to express foreign antigens of other pathogens and deliver them to the immune system. Strain Ty21a has served as a prototype in clinical and field trials to identify the optimal formulations and dosage schedules for live vaccines and to quantitate the duration of protection that can be achieved. Clinical trials with three new attenuated S. typhi candidate vaccines, a Vi+ variant of Ty21a, an aroC,aroD double mutant recombinant strain and a cya,crp double mutant, are underway or will be initiated shortly.
